Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
9 studies found for:    "Toxic epidermal necrolysis"
Show Display Options
Rank Status Study
1 Completed Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Conditions: Stevens-Johnson Syndrome;   Toxic Epidermal Necrolysis
Intervention: Drug: Intravenous immunoglobulin
2 Terminated Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
Conditions: Toxic Epidermal Necrolysis;   Stevens-Johnson Syndrome
Intervention: Drug: Palifermin
3 Withdrawn Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
Condition: Toxic Epidermal Necrolysis
Intervention: Drug: Remicaide (infliximab)
4 Not yet recruiting Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
Condition: Toxic Epidermal Necrolysis
Intervention: Drug: Clobetasol 0.05% ointment
5 Not yet recruiting Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study
Condition: Toxic Epidermal Necrolysis
Interventions: Drug: Isotretinoin;   Other: Placebo
6 Recruiting Severe Cutaneous Adverse Reactions in Thailand
Conditions: Steven-Johnson Syndrome;   Toxic Epidermal Necrolysis;   Drug Reaction With Eosinophilia and Systemic Symptoms;   Acute Generalized Exanthematous Pustulosis;   Generalized Bullous Fixed Drug Eruption
Intervention:
7 Enrolling by invitation Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
Conditions: Stevens-Johnson Syndrome;   Toxic Epidermal Necrolysis (Lyell) Syndrome;   Mucous Membrane Pemphigoid
Intervention: Drug: topical infliximab
8 Not yet recruiting G-CSF in the Treatment of Toxic Epidermal Necrolysis
Condition: Stevens - Johnson Syndrome
Interventions: Drug: recombinant granulocyte - colony stimulating factor;   Drug: NaCl 0.9%
9 Withdrawn Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
Conditions: Stevens-Johnson Syndrome;   Corneal Blindness
Intervention: Drug: Infliximab

Indicates status has not been verified in more than two years